Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06781333 · ClinicalTrials.gov registry record · Phase 2
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
A Phase 2 study of Alzheimer Disease and Agitation in Dementia, sponsored by Bernard (Barry) Baumel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06781333: Recruiting Phase 2 study of Alzheimer Disease and Agitation in Dementia, sponsored by Bernard (Barry) Baumel.
NCT06781333 is a Phase 2 study of Alzheimer Disease and Agitation in Dementia that is actively recruiting participants, run by Bernard (Barry) Baumel. The registered enrollment target is 8 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06781333, a Phase 2 study of Alzheimer Disease and Agitation in Dementia, is actively recruiting participants, sponsored by Bernard (Barry) Baumel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
Primary Outcome
Score ranges from 0-12, higher scores indicate a worse psychiatric outcome
Conditions Studied
Interventions
- BIOLOGICAL hMSC
Study Locations (1)
Florida
- University of Miami Department of Neurology - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
What NCT06781333 shows while recruiting
NCT06781333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which hMSC is the first listed.
NCT06781333 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06781333 about?
NCT06781333 is a clinical study titled "Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.". The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
What is the current status of trial NCT06781333?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2025-04-29. Estimated completion is 2026-06-15.
What conditions does trial NCT06781333 study?
This clinical trial studies the following conditions: Alzheimer Disease, Agitation in Dementia.
What interventions are being tested in trial NCT06781333?
The interventions under investigation include: hMSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT06781333?
This trial is sponsored by Bernard (Barry) Baumel, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06781333 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06781333's enrollment target sits among peer trials
8 296th of 306 higher than 8 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI